Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $12.8500 (9.64%) ($11.4400 - $13.5100) on Mon. Apr. 20, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.24% (three month average) | RSI | 63 | Latest Price | $12.8500(9.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 5.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(57%) ARKK(54%) IBB(54%) IBUY(52%) | Factors Impacting TGTX price | TGTX will decline at least -3.62% in a week (0% probabilities). VIXM(-33%) VXX(-31%) UUP(-15%) TLT(-1%) IYT(0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.62% (StdDev 7.24%) | Hourly BBV | 0 () | Intraday Trend | 12.3% | | | |
|
5 Day Moving Average | $11.15(15.25%) | 10 Day Moving Average | $10.61(21.11%) | 20 Day Moving Average | $10.13(26.85%) | To recent high | -19.6% | To recent low | 80% | Market Cap | $1.627b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |